New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics … – GlobeNewswire (press release)
|
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics …
GlobeNewswire (press release) ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications. SEATTLE and LUND, Sweden, May 08, 2018 (GLOBE NEWSWIRE) — Aptevo Therapeutics Inc. (Nasdaq:APVO), … |
